## Nephrotoxicity Comparison: Tobramycin vs. Gentamicin ### Mechanism of Aminoglycoside Nephrotoxicity **Key Point:** Aminoglycoside nephrotoxicity is concentration-dependent and mediated by proximal tubule uptake via megalin-mediated endocytosis, followed by mitochondrial dysfunction, oxidative stress, and acute tubular necrosis (ATN). The risk is proportional to cumulative renal cortical accumulation. ### Comparative Nephrotoxicity Profile | Feature | Gentamicin | Tobramycin | |---------|-----------|----------| | **Nephrotoxicity Incidence** | 8–26% (dose and duration dependent) | 4–8% (lower than gentamicin) | | **Proximal Tubule Accumulation** | High; concentrates in cortex | Lower; less tubular uptake | | **Nephrotoxicity Index** | ~2.5–3.0 (higher risk) | ~1.5–2.0 (lower risk) | | **Renal Half-life** | 40–50 hours (renal) | 35–40 hours (renal) | | **Protein Binding** | <10% (mostly free) | <10% (mostly free) | | **Recovery** | Often reversible if caught early | Similar reversibility | **High-Yield:** Tobramycin has a **lower nephrotoxicity index** than gentamicin because it accumulates less in the proximal tubule cortex despite similar renal clearance rates. This makes tobramycin the preferred aminoglycoside in patients with renal impairment or high nephrotoxicity risk. ### Clinical Pearl In this patient with CKD (eGFR 28), tobramycin would be preferred over gentamicin if an aminoglycoside is deemed necessary. However, the ideal approach is to avoid aminoglycosides altogether in advanced CKD and use fluoroquinolones (e.g., ciprofloxacin for *Pseudomonas*) or β-lactams (e.g., piperacillin-tazobactam, ceftazidime) as first-line agents. If aminoglycosides are unavoidable, extended-interval dosing (once daily) and therapeutic drug monitoring are essential. **Mnemonic:** **TOBY's CORTEX** = **TO**bramycin **B**etter **Y**ields lower **CORTEX** accumulation.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.